Entity

Time filter

Source Type


Wang X.,The Peoples Hospital of Anyang City | He X.J.,The First Peoples Hospital of Shangqiu | Xu H.Q.,The Peoples Hospital of Anyang City | Chen Z.W.,ICU | Fan H.H.,ICU
Genetics and Molecular Research | Year: 2016

The aim of this study was to explore the inhibition of subcutaneously implanted human pituitary tumor cells in nude mice by LRIG1 and its mechanism. For this study, athymic nude mice were injected with either normal pituitary tumor RC-4B/C cells or LRIG1-transfected RC-4B/C cells. We then calculated the volume inhibition rate of the tumors, as well as the apoptosis index of tumor cells and the expression of Ras, Raf, AKt, and ERK mRNA in tumor cells. Tumor cell morphological and structural changes were also observed under electron microscope. Our data showed that subcutaneous tumor growth was slowed or even halted in LRIG1-transfected tumors. The tumor volumes were significantly different between the two groups of mice (χ2 = 2.14, P < 0.05). The tumor apoptosis index was found to be 8.72% in the control group and 39.7% in LRIG1-transfected mice (χ2 = 7.59, P < 0.05). The levels of Ras, Raf, and AKt mRNA in LRIG1-transfected RC-4B/C cells were significantly reduced after transfection (P < 0.01). Transfected subcutaneous tumor cells appeared to be in early or late apoptosis under an electron microscope, while only a few subcutaneous tumor cells appeared to be undergoing apoptosis in the control group. In conclusion, the LRIG1 gene is able to inhibit proliferation and promote apoptosis in subcutaneously implanted human pituitary tumors in nude mice. The mechanism of LRIG1 may involve the inhibition of the PI3K/ Akt and Ras/Raf/ERK signal transduction pathways. © FUNPEC-RP. Source


Zhang J.,Zhengzhou University | Gu Z.,Zhengzhou University | Xue L.,The First Peoples Hospital of Shangqiu | Dong T.,Zhengzhou University | And 2 more authors.
International Journal of Clinical and Experimental Medicine | Year: 2016

Inflammatory mediators play key roles in neuropathic pain of the trigeminal system. Anesthetic isoflurane (ISO) possesses anti-inflammatory activity. However, the inhibitory effects of ISO on inflammation-triggered neuropathic pain are unclear. In this study, we investigated the effects of 1.4% ISO on neuropathic pain in interleukin-1β (IL-1β)-challenged primary rat trigeminal ganglia cells (TGCs). Here, we found that ISO reduced the mRNA and protein levels of cyclooxygenase-2 (COX-2) and C-C motif ligand 2 (CCL2) in IL-1β-stimulated TGCs, as determined by quantitative real-time PCR and Western blot, respectively. Enzyme-linked immunosorbent assays showed that IL-1β-induced prostaglandin E2 (PGE2), CCL2, and calcitonin gene-related peptide (CGRP) release from TGCs was significantly inhibited by ISO treatment. Pretreatment with a selective inhibitor of COX-2 (parecoxib) notably attenuated IL-1β-induced PGE2 and CGRP release in TGCs. Pretreatment with an inhibitor of CCL2 synthesis (bindarit) also reduced CGRP release in IL-1β-challenged TGCs. Collectively, ISO ameliorates neuropathic pain through reduction of CGRP release by inhibiting COX-2 activity and CCL2 production in IL-1β-treated TGCs. © 2016, E-Century Publishing Corporation. All rights reserved. Source


Zhu L.,The First Peoples Hospital of Shangqiu
Zhonghua nan ke xue = National journal of andrology | Year: 2013

To investigate the incidence and spermatogenesis of cryptorchid testes induced by postnatal injection of estradiol. Ninety male newborn Balb/C mice were randomly divided into an experimental (n = 60), a solvent control (n = 20) and a normal control group (n = 10). The experimental mice were again assigned to a 4-week, a 6-week, an 8-week, and a 10-week subgroup, and injected subcutaneously with 17-beta estradiol (5 microg/d) from 3 to 28, 3 to 42, 3 to 56 and 3 to 70 days after birth, respectively. The incidence of cryptorchidism and morphological changes of the testes were observed at 2 weeks after drug withdrawal. The incidence rates of cryptorchidism in the 4-, 6-, 8- and 10-week groups were 0%, 26.7%, 60% and 60%, respectively, but no cryptorchidism occurred in the solvent and normal control groups. The 4- and 6-week groups showed autonomous descent of the cryptorchid testes and recovery of spermatogenesis after drug withdrawal. The models became stable and no spermatogenesis recovery was observed after 8 weeks of continuous medication. Stable cryptorchid infertile models can be established in mice by postnatally continuous injection of estradiol for over 8 weeks. Source


Zhang T.T.,The First Peoples Hospital of Shangqiu | Wang R.M.,The First Peoples Hospital of Shangqiu | Yang Z.,Zhengzhou University | Chen G.B.,The First Peoples Hospital of Shangqiu
Clinical and Translational Oncology | Year: 2015

Background: The strategy of dual inhibiting epidermal growth factor receptor (EGFR) and vascular endothelial growth factor (VEGF) pathways has been extensively investigated in advanced non-small-cell lung cancer (NSCLC), but the benefit-to-risk ratio of dual-targeted regimen versus EGFR-tyrosine kinase inhibitors (TKIs) alone is still unclear. We thus perform this meta-analysis to assess the efficacy and safety of this regimen versus EGFR-TKIs alone in those patients. Methods: Databases from PubMed, Web of Science and the Cochrane Library up to March 31, 2015 were searched to identify relevant studies. Eligible studies included prospective randomized controlled trials (RCTs) evaluating dual inhibiting EGFR and VEGF pathways versus EGFR-TKIs alone in advanced NSCLC. The endpoints were overall survival (OS), progression-free survival (PFS), objective response rate (ORR) and grade 3 or 4 adverse events. Statistical analyses were conducted by using either random effects or fixed effect models according to the heterogeneity of included studies. Results: A total of 1918 patients with advanced NSCLC from 4 RCTs were identified for the analysis. The pooled results demonstrated that dual inhibiting EGFR and VEGF pathways significantly improved the PFS (HR 0.71, 95 % CI 0.58–0.86, p < 0.001) and ORR (OR 1.54, 95 % CI 1.14–2.08, p = 0.005) in unselected NSCLC when compared to EGFR-TKIs alone, but it did not translate into OS benefit (HR 0.94, 95 % CI 0.84–1.05, p = 0.24). No evidence of publication bias was observed. Conclusions: Our study suggests that dual inhibition of EGFR and VEGF pathways significantly improves PFS and ORR, but it does not translate into survival benefit in unselected NSCLC patients. Prospective clinical trials investigating the role of this regimen in EGFR mutation-positive NSCLC are still warranted. © 2015 Federación de Sociedades Españolas de Oncología (FESEO) Source


Cao J.,Nanjing Agricultural University | Feng C.,The First Peoples Hospital of Shangqiu | Liu Y.,Clinical Laboratory | Wang S.,Nanjing University of Science and Technology | Liu F.,Nanjing Agricultural University
Biosensors and Bioelectronics | Year: 2014

Since many diseases are caused by pathogenic bacterial infections, accurate and rapid detection of pathogenic bacteria is in urgent need to timely apply appropriate treatments and to reduce economic costs. To end this, we designed molecular beacon-Au nanoparticle hybrid nanoprobes to improve the bacterial detection efficiency and sensitivity. Here, we show that the designed molecular beacon modified Au nanoparticles could specifically recognize synthetic DNAs targets and can readily detect targets in clinical samples. Moreover, the hybrid nanoprobes can recognize Escherichia coli within an hour at a concentration of 102cfu/ml, which is 1000-folds sensitive than using molecular beacon directly. Our results show that the molecular beacon-Au nanoparticle hybrid nanoprobes have great potential in medical and biological applications. © 2014 Elsevier B.V. Source

Discover hidden collaborations